WO1998030530A1 - Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them - Google Patents
Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- WO1998030530A1 WO1998030530A1 PCT/IL1997/000427 IL9700427W WO9830530A1 WO 1998030530 A1 WO1998030530 A1 WO 1998030530A1 IL 9700427 W IL9700427 W IL 9700427W WO 9830530 A1 WO9830530 A1 WO 9830530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- acid
- active ingredient
- pharmaceutical compositions
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/602—Dicarboxylic acid esters having at least two carbon-to-carbon double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
Definitions
- a novel class of compounds has been found to be effective in treating hyperlipidemia, obesity and impaired glucose tolerance/noninsulin dependent diabetes mellitus without adversely affecting energy metabolism.
- the active compounds have the general formula
- R r R 4 each independently represents a hydrogen or an unsubstituted or substituted hydrocarbyl or heterocyclyl radical
- R 5 and R 6 independently represent hydrogen, hydroxyl, lower alkyl, chloro, bromo, cyano, nitro, lower alkoxy, or trifluoromethyl
- Q represents a diradical consisting of a linear chain of 2 to 14 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteroatom chain members optionally forming part of a ring structure and where one or both of the carboxyl groups can be substituted by an in vivo hydrolyzable physiologically acceptable substituent.
- the invention also provides pharmaceutical compositions comprising the aforementioned compounds of formula (I) for the treatment of obesity, hyperlipidemia and maturity-onset diabetes.
- Dyslipoproteinemia combined hypercholesterolemia-hypertriglyceridemia), low HDL-cholesterol), obesity (in particular upper body obesity), impaired glucose tolerance (IGT) leading to noninsulin-dependent diabetes mellitus (NIDDM)) and essential hypertension are common diseases that afflict individuals living in Westernized societies. Being initiated and linked through hyper-insulinemia these four diseases often coexist and precipitate independently as well as synergistically atherosclerotic vascular disease leading to coronary heart disease. The incidence of the Deadly quartet ( Syndrome-X , Metabolic Syndrome ) comprising the four diseases increases as the population ages and by 70 years of age reaches epidemic proportions.
- hypertriglyceridemia-hyper- cholesterolemia which comprise of >70% of dyslipoproteinemic patients
- isolated hypertriglyceridemia with reduced plasma HDL as well as for the postprandial chylomicrons-rich phase realized now as an independent risk for atherosclerotic cardiovascular disease.
- Isolated hyper-triglyceridemia may however be treated with either nicotinic acid or drugs of the fibrate family.
- the compliance for nicotinic acid is very poor and the advantage of fibrate drugs in lowering overall mortality has been seriously questioned since the exhaustive WHO clofibrate study.
- nicotinic acid is ineffective while fibrate drugs are only poorly effective in reducing plasma cholesterol, thus leaving the combined hypertriglyceridemic-hypercholesterolemic patient with the only choice of a combination treatment mode (e.g., HMG-CoA reductase inhibitor/nicotinic acid).
- a combination treatment mode e.g., HMG-CoA reductase inhibitor/nicotinic acid.
- Weight reduction measures are essentially based on promoting dietary or behavioral means for reducing weight.
- most obese individuals turn out to respond inadequately to dietary or behavioral measures, especially if examined over long time periods.
- the chances for 5-year maintenance of weight reduction initiated by dietary and behavior modifications are less than 10%.
- This overwhelming failure is mainly metabolic, since the decrease in weight as a result of dieting is always accompanied by a decrease in basal metabolic rate and overall energy expenditure, thus forcing the dieting obese patient into a genuine deadlock.
- Antiobesity drugs based on modulating energy intake are currently based on anorectics designed to depress the hypothalamic satiety center. These drugs are reported to be ineffective in the medium and long range and some may induce primary pulmonary hypertension.
- thermogenic ⁇ 3-adrenergic agonists are selected on the basis of their capacity to stimulate brown adipose tissue ⁇ -adreno receptors and may indeed induce thermogenesis in rodents.
- efficacy of such agents in humans while allowing free access to calories is still questionable and their broad tissue specificity (e.g., skeletal muscle, myocardium, colon) may be expected to result in nonspecific-adrenergic-induced effects.
- the sulphonylurea (similarly to insulin) tend to promote weight gain, thus further promoting insulin resistance and compensatory hyperinsulinemia leading to diabetes-induced macrovascular disease (atherosclerotic cardiovascular disease).
- Biguanides are claimed to potentiate insulin-mediated glucose disposal with no stimulation of pancreatic insulin secretion.
- the use of biguanides as monotherapy is not unanimously recommended except for the very obese in light of their low therapeutic/toxicity index and the induction of lactic acidosis.
- ⁇ , ⁇ -Dialkanoic acids of chain length of 14 20 carbon atoms which are hydrocarbyl substituted on the ⁇ , ⁇ carbon atoms, as well as their salts and ester derivatives were disclosed in Bar-Tana U.S. Patent Nos. 4,634,795, 4,689,344 and 4,711,896 as possessing a hypolipidemic, weight reducing and antidiabetogenic activity.
- Treatment of the Metabolic Syndrome and its related pathologies would require chronic dosing has initiated an exhaustive search for new compounds having a higher efficacy as compared with the previously disclosed ⁇ , ⁇ '-substituted cx, ⁇ dialkanoic acids.
- a novel class of compounds has now been found, in accordance with the present invention, to be surprisingly effective in reducing blood lipids.
- the new compounds of the invention were also found to have a calorigenic antidiabetic (NIDDM) activity without adversely affecting energy metabolism.
- NIDDM calorigenic antidiabetic
- the efficacy of some of these compounds is far better as compared with previously reported ⁇ , ⁇ '-substituted ⁇ , ⁇ -dialkanoic acids.
- novel compounds provided by the present invention are ⁇ , ⁇ -dialkanoic acids having the general formula
- R ⁇ -R 4 each independently represents a hydrogen or an unsubstituted or substituted hydrocarbyl; where R 5 and R 6 independently represent hydrogen, hydroxyl, lower alkyl, chloro, bromo, cyano, nitro, lower alkoxy, or trifluoromethyl;
- Q represents a diradical consisting of a liner chain of 2 to 14 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteroatom chain members optionally forming part of a ring structure.
- salts with pharmaceutically acceptable inorganic or organic cations in particular alkali metal salts, alkaline earth metal salts, ammonium salts and substituted ammonium salts; esters, particularly lower alkyl esters; amides, mono- and di- substituted amides; and anhydrides, e.g., with lower alkanoic acids; and lactones formed by ring closure of either or both carboxylic groups with a free hydroxy substituent (or substituents) in the molecule of formula (I).
- hydrocarbyl in the definition of R R 4 includes, e.g., optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl and the like.
- a preferred group of compounds in accordance with the invention are those of formula (I) above in which R1-R 4 are each lower alkyl and Q is a straight polymethylene chain of 2 to 14 carbon atoms; and in vivo hydrolysable functional derivatives thereof.
- Especially preferred compounds of the present invention are those of the general formula
- n is an integer from
- n is an integer from 10-16; and their in vivo hydrolyzable function derivatives.
- novel compounds of formula (I) according to the invention can be prepared by methods known ?er_?e, some of which are illustrated in the examples herein.
- the present invention provides pharmaceutical compositions for the treatment of obesity, hyperlipidemia, diabetes or the Metabolic Syndrome, comprising as active ingredients the novel compounds of formula (I) above together with pharmaceutical carriers or diluents.
- the pharmaceutical compositions are primarily for oral administration, but may also be for parenteral or topical administration.
- These pharmaceutical compositions, which are preferably in dosage unit form, may be in the form of, e.g., tablets, capsules, lozenges, pills, powders and aqueous and non-aqueous solutions or suspensions.
- compositions of this invention preferably comprise also conventional pharmaceutical solid or liquid carriers or diluents, e.g., gelatin, sugars, starches, cellulose derivatives, fatty acids and their salts, vegetable oils, glycerine, glycols, water, aqueous saline or phosphate buffer solutions and the like.
- the compositions may also comprise other compatible substances normally used in pharmaceutical formulations and also other additives, such as colouring agents, flavouring agents and preservatives.
- compositions according to the invention are preferably in dosage unit form, each unit containing from 50 to 500 mg of the active ingredient of the formula (I) above.
- the daily dosage of the compounds of formula (I) above according to the invention will depend on the age, needs and tolerance of the individual patient, but will usually range from 50 mg to from 5,000 mg per day.
- the pharmacological activities of the compounds of formula (I) according to the invention could be demonstrated by means of in vivo experiments in rats and in vitro experiments in liver cells in accordance with standard methods. Some of these experiments are described hereinafter in detail.
- the biological effect in vivo was evaluated by following food intake, plasma triglycerides, plasma cholesterol and plasma glucose. The results are shown in the following Table I.
- the biological effect in vivo was evaluated by following plasma triglycerides, plasma apolipoprotein(apo)C-III, plasma insulin and the steady state concentrations (Css) of the respective drugs in plasma.
- Fold efficacy represents the respective effect induced by the ⁇ , ⁇ -substituted compound (Ex. 5) relative to that of the ⁇ , ⁇ -substituted compound.
- the active compounds are potent hypolipidemics.
- the overall hypolipidemic effect is based on activating plasma lipoproteins clearance resulting from decrease in plasma apo C-III.
- the active compounds are potent insulin sensitizers as reflected by plasma insulin concentrations required for maintaining euglycemia. Insulin sensitization may form the basis for using these compounds in the treatment of IGT/NIDDM.
- the active compounds induce increase in calorigenesis as a result of decrease in mitochondrial membrane potential. Uncoupling induced by these compounds may form the basis for using these compounds in the treatment of obesity.
- Potassium carbonate (56 g) was added portionwise over 1 h to a stirred mixture of 68 g (0.94 mol) of freshly distilled isobutyraldehyde and 70 ml of 40% formalin under argon. During addition the temperature was kept at 10 15°C. The temperature was allowed to rise to 25°C while stirring was further continued under argon for 12 h, followed by adding 100 ml water to the white suspension. The mixture was extracted four times with 40 ml of chloroform and the combined extracts were dried over magnesium sulfate and concentrated in vacuo.
- Hexane-1,6 bis(triphenyl-phosphonium) dibromide (8.28 g, 0.011 mol) (dried over phosphorus pentoxide at least for 36 h) and 550 ml of dry tetrahydrofuran (refluxed over lithium aluminum hydride and distilled at atmosphere pressure) were placed in a dry 1-L three necked flask flushed with argon and vigorously stirred under argon until a fine suspension was formed. Then 17 ml of 1.375 M solution of phenyllithium in ether was added dropwise during 30 min.
- Octane-1,8 bis (triphenyl-phosphonium) dibromide 14.34 g, 0.018 mol) (dried in a vacuum desiccator over phosphorus pentoxide at least for 10 days) and 400 ml of dry tetrahydrofuran (refluxed over lithium aluminum hydride and distilled at atmosphere pressure) were placed in a dry 1-L three necked flask flushed with argon and vigorously stirred under argon until a fine suspension was formed. Then 20 ml of 1.86 M solution of phenyllithium in ether was added dropwise during 30 min.
- 1,14-Dibromotetradecane was prepared by adding HBr into a solution of 4.0 g (20.6 mmol) of 1,13-tetradecadiene and 0.5 g of benzoyl peroxide in benzene at room temperature. The mixture was stirred for two hours and chromatographed on A1 2 0 3 (4 12 cm) with benzene eluent. 1,14 Dibromotetradecane was isolated and recrystallized from hexane to yield 6.8 g (93.1%), m.p. 50°C.
- 2,2,17,17-Tetra-methyloctadecanedioic acid was synthesized by adding dropwise 17.5 ml (30 mmol) of 1.72 N solution of butyllithium in hexane to 3.0 g (30 mmol) of diisopropyl-amine in 40 ml of THF in an Ar atmosphere at 15-5°C. Following 30 min the mixture was cooled to 20°C and 1.3 g (15 mmol) of isobutyric acid were added. The temperature was gradually increased to 20°C and stirring was continued for three hours. The reaction mixture was cooled again to -15°C followed by adding the prepared 1,14-dibromotetradecane (0.2 g, 3.4 mmol) in one portion.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/331,895 US6284903B1 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JP53069798A JP2001507713A (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and their derivatives and pharmaceutical compositions containing them |
AU79947/98A AU742945B2 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions contai ning them |
CA2277075A CA2277075C (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
KR1019997006147A KR100806928B1 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
DE69739415T DE69739415D1 (en) | 1997-01-07 | 1997-12-25 | Carbone acids and their derivatives and pharmaceutical compositions containing them |
EP97949080A EP0988274B1 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
AT97949080T ATE431816T1 (en) | 1997-01-07 | 1997-12-25 | CARBONIC ACIDS AND THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11997197A IL119971A (en) | 1997-01-07 | 1997-01-07 | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
IL119971 | 1997-01-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/331,895 A-371-Of-International US6284903B1 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US09/881,812 Continuation US6800772B2 (en) | 1997-01-07 | 2001-06-18 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998030530A1 true WO1998030530A1 (en) | 1998-07-16 |
Family
ID=11069666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL1997/000427 WO1998030530A1 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
Country Status (10)
Country | Link |
---|---|
US (3) | US6284903B1 (en) |
EP (2) | EP2112134B1 (en) |
JP (2) | JP2001507713A (en) |
KR (2) | KR100806927B1 (en) |
AT (1) | ATE431816T1 (en) |
AU (1) | AU742945B2 (en) |
CA (1) | CA2277075C (en) |
DE (1) | DE69739415D1 (en) |
IL (1) | IL119971A (en) |
WO (1) | WO1998030530A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303653B1 (en) | 1997-06-26 | 2001-10-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US6673780B2 (en) | 2000-10-11 | 2004-01-06 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US6699910B2 (en) | 2000-10-11 | 2004-03-02 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
WO2004067489A2 (en) * | 2003-01-23 | 2004-08-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
WO2008147807A2 (en) | 2007-05-23 | 2008-12-04 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
US9610251B2 (en) | 2011-11-01 | 2017-04-04 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2017208232A1 (en) | 2016-06-02 | 2017-12-07 | Syndromex Ltd. | DIABETES TREATMENT REGIMENS USING α,α-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US20190039989A1 (en) * | 2016-02-25 | 2019-02-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, preparation method therefor and use therefor |
US10512624B2 (en) | 2016-11-30 | 2019-12-24 | Syndromex Ltd. | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 |
US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US11116739B2 (en) | 2015-03-16 | 2021-09-14 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease |
US11407705B2 (en) | 2019-06-21 | 2022-08-09 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6814962B1 (en) * | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
IL119971A (en) * | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
US20090018199A1 (en) * | 2003-12-30 | 2009-01-15 | Syndrome X Ltd. | Methods of Administering 3, 3, 14, 14 Tetramethyl Hexadecane 1, 16 Dioic Acid |
IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
CA2812109A1 (en) | 2010-09-20 | 2012-03-29 | Kareus Therapeutics, Sa | Methods and compositions for treatment of diabetes and dyslipidemia |
US10479752B2 (en) * | 2011-12-08 | 2019-11-19 | Syndromex Ltd. | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US4634795A (en) * | 1981-12-15 | 1987-01-06 | Epis S.A. | Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US4711896A (en) * | 1984-06-22 | 1987-12-08 | Epis S.A. | α, ω-dicarboxylic acids and medicaments which contain these compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1268082A (en) | 1969-08-08 | 1972-03-22 | Orsymonde | Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes |
BE755550A (en) * | 1969-09-02 | 1971-02-01 | Parke Davis & Co | ALKANEDIOIC ACIDS, THEIR SALTS AND THEIR ESTERS REDUCING THE TRIGLYCERIDE CONTENT IN BLOOD SERUM |
US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
FR2288516A2 (en) | 1974-10-21 | 1976-05-21 | Orsymonde | Normolipaemic 1,10-bis-(carboxyalkylene-thio) - decanes - used to treat atherosclerosis and coronary artery troubles |
US4634975A (en) * | 1984-09-17 | 1987-01-06 | Progressive Dynamics, Inc. | Method and apparatus for producing electromagnetic surveillance fields |
JPS61171417A (en) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | Antidiabetic |
DE3512536A1 (en) * | 1985-04-06 | 1986-10-16 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3634356A1 (en) * | 1986-10-08 | 1988-04-21 | Epis Sa | MEDICINE CONTAINING ALPHA-HALOGENED DICARBONIC ACIDS |
DE4224670A1 (en) * | 1992-07-25 | 1994-01-27 | Boehringer Mannheim Gmbh | Use of â, w-dicarboxylic acids as fibrinogens |
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
IL119971A (en) * | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
JP2003001549A (en) * | 2001-06-26 | 2003-01-08 | Howa Mach Ltd | Cutter breakage detecting device of photoelectric type |
-
1997
- 1997-01-07 IL IL11997197A patent/IL119971A/en not_active IP Right Cessation
- 1997-12-25 US US09/331,895 patent/US6284903B1/en not_active Expired - Lifetime
- 1997-12-25 JP JP53069798A patent/JP2001507713A/en not_active Withdrawn
- 1997-12-25 CA CA2277075A patent/CA2277075C/en not_active Expired - Fee Related
- 1997-12-25 EP EP09160514.7A patent/EP2112134B1/en not_active Expired - Lifetime
- 1997-12-25 KR KR1020077003601A patent/KR100806927B1/en not_active IP Right Cessation
- 1997-12-25 DE DE69739415T patent/DE69739415D1/en not_active Expired - Lifetime
- 1997-12-25 WO PCT/IL1997/000427 patent/WO1998030530A1/en not_active Application Discontinuation
- 1997-12-25 AU AU79947/98A patent/AU742945B2/en not_active Ceased
- 1997-12-25 AT AT97949080T patent/ATE431816T1/en not_active IP Right Cessation
- 1997-12-25 KR KR1019997006147A patent/KR100806928B1/en not_active IP Right Cessation
- 1997-12-25 EP EP97949080A patent/EP0988274B1/en not_active Expired - Lifetime
-
2001
- 2001-06-18 US US09/881,812 patent/US6800772B2/en not_active Expired - Lifetime
-
2003
- 2003-10-08 US US10/680,429 patent/US20040132818A1/en not_active Abandoned
-
2009
- 2009-11-16 JP JP2009260665A patent/JP5479857B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US4634795A (en) * | 1981-12-15 | 1987-01-06 | Epis S.A. | Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US4689344A (en) * | 1981-12-15 | 1987-08-25 | Epis S.A. | Long-chain α,ω-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US4711896A (en) * | 1984-06-22 | 1987-12-08 | Epis S.A. | α, ω-dicarboxylic acids and medicaments which contain these compounds |
Non-Patent Citations (4)
Title |
---|
DATABASE CA ON STN, No. 77:61278, BORGEN et al., "Synthesis of Bis (Gem-Dimethyl) Cycloalkanones and Tetrakis (Gem-Dimethyl) Cycloalkanediones"; & ACTA CHEM. SCAND., 1972. * |
DATABASE CA ON STN, No. 82:155110, BJORNSTAD et al., "Bis (Gem-Dimethyl)-Substituted Cyclic Diynes"; & ACTA CHEM. SCAND. SER. B., 1975. * |
DATABASE CA ON STN, No. 83:178236, NEWKOME et al., "Improved Synthesis of Alpha, Alpha, Alpha, Tetramethyldicarboxylic Acids"; & SYNTHESIS, 1975. * |
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, November 1950, Vol. 72, No. 11, NELSON et al., "The Influence of Steric Configuration on the Ultraviolet Absorption of 1,2-Diketones", pages 5388-5397. * |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303653B1 (en) | 1997-06-26 | 2001-10-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US6506799B1 (en) | 1999-04-01 | 2003-01-14 | Esperion Therapeutics, Inc. | Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds |
US6790953B2 (en) | 1999-04-01 | 2004-09-14 | Esperion Therapeutics, Inc. | Ether compounds |
US7192940B2 (en) | 1999-04-01 | 2007-03-20 | Esperion Therapeutics, Inc. | Ether compounds |
US6646170B2 (en) | 1999-04-01 | 2003-11-11 | Esperion Therapeutics, Inc. | Intermediates for the synthesis of ether compounds |
US6459003B1 (en) | 1999-04-01 | 2002-10-01 | Esperion Therapeutics, Inc. | Ether compounds |
US6909014B2 (en) | 1999-04-01 | 2005-06-21 | Esperion Therapeutics, Inc. | Intermediates for the synthesis of ether compounds |
US6831105B2 (en) | 1999-04-01 | 2004-12-14 | Esperion Therapeutics, Inc. | Compositions comprising ether compounds and pharmaceutical uses therefor |
US7709515B2 (en) | 1999-04-01 | 2010-05-04 | Esperion Therapeutics, Inc. | Compositions comprising ether compounds and pharmaceutical uses therefor |
US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US6673780B2 (en) | 2000-10-11 | 2004-01-06 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US6699910B2 (en) | 2000-10-11 | 2004-03-02 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US9006290B2 (en) | 2003-01-23 | 2015-04-14 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US10118881B2 (en) | 2003-01-23 | 2018-11-06 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7335799B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7335689B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US7405226B2 (en) | 2003-01-23 | 2008-07-29 | Pfizer Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US9452964B2 (en) | 2003-01-23 | 2016-09-27 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US7576130B2 (en) | 2003-01-23 | 2009-08-18 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US9000041B2 (en) | 2003-01-23 | 2015-04-07 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
WO2004067489A3 (en) * | 2003-01-23 | 2004-11-25 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7812199B2 (en) | 2003-01-23 | 2010-10-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7838554B2 (en) | 2003-01-23 | 2010-11-23 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US10047028B2 (en) | 2003-01-23 | 2018-08-14 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US10941095B2 (en) | 2003-01-23 | 2021-03-09 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US8067466B2 (en) | 2003-01-23 | 2011-11-29 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management |
WO2004067489A2 (en) * | 2003-01-23 | 2004-08-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
EP2402300A1 (en) | 2003-01-23 | 2012-01-04 | Esperion Therapeutics Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
EP2404890A1 (en) | 2003-01-23 | 2012-01-11 | Esperion Therapeutics Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7119221B2 (en) | 2003-01-23 | 2006-10-10 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US9624152B2 (en) | 2003-01-23 | 2017-04-18 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US8623915B2 (en) | 2003-01-23 | 2014-01-07 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US8309604B2 (en) | 2003-01-23 | 2012-11-13 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US8497301B2 (en) | 2003-01-23 | 2013-07-30 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US8975300B2 (en) | 2003-12-24 | 2015-03-10 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US8642653B2 (en) | 2003-12-24 | 2014-02-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US8084498B2 (en) | 2003-12-24 | 2011-12-27 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
US8889698B2 (en) | 2007-02-01 | 2014-11-18 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
US10532054B2 (en) | 2007-02-01 | 2020-01-14 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
US9199990B2 (en) | 2007-02-01 | 2015-12-01 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
EP2431043A1 (en) | 2007-05-23 | 2012-03-21 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption |
WO2008147807A2 (en) | 2007-05-23 | 2008-12-04 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US11407719B2 (en) | 2009-03-18 | 2022-08-09 | Resverlogix Corp. | Anti-inflammatory agents |
US10882828B2 (en) | 2009-03-18 | 2021-01-05 | Resverlogix Corp. | Anti-inflammatory agents |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
US10131640B2 (en) | 2009-03-18 | 2018-11-20 | Resverlogix Corp. | Anti-inflammatory agents |
US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
EP3358008A1 (en) | 2009-09-03 | 2018-08-08 | Pfizer Vaccines LLC | Pcsk9 vaccine |
EP2865752A1 (en) | 2009-09-03 | 2015-04-29 | Pfizer Vaccines LLC | PCSK9 vaccine |
WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
US9610251B2 (en) | 2011-11-01 | 2017-04-04 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
US10016426B2 (en) | 2011-11-01 | 2018-07-10 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
US9278940B2 (en) | 2012-11-21 | 2016-03-08 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
US11696941B2 (en) | 2014-02-11 | 2023-07-11 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
US10925938B2 (en) | 2014-02-11 | 2021-02-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Composition comprising PCSK9 peptide conjugated to a Qbeta carrier and methods of using the same |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US11744816B2 (en) | 2015-03-13 | 2023-09-05 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US10772894B2 (en) | 2015-03-13 | 2020-09-15 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US11116739B2 (en) | 2015-03-16 | 2021-09-14 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease |
US10414713B2 (en) * | 2016-02-25 | 2019-09-17 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, preparation method therefor and use therefor |
US20190039989A1 (en) * | 2016-02-25 | 2019-02-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, preparation method therefor and use therefor |
IL263061B2 (en) * | 2016-06-02 | 2023-02-01 | Syndromex Ltd | Diabetes treatment regimens using a,a-substituted long-chain amphipathic carboxylates |
US11207285B2 (en) | 2016-06-02 | 2021-12-28 | Syndromex Ltd. | Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates |
IL263061B (en) * | 2016-06-02 | 2022-10-01 | Syndromex Ltd | Diabetes treatment regimens using a,a-substituted long-chain amphipathic carboxylates |
EP3463330A4 (en) * | 2016-06-02 | 2020-01-15 | Syndromex Ltd. | Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates |
CN109195595A (en) * | 2016-06-02 | 2019-01-11 | 塞多麦克斯有限公司 | Using α, the treating diabetes scheme of the amphipathic carboxylate of the long-chain of alpha-substituted |
WO2017208232A1 (en) | 2016-06-02 | 2017-12-07 | Syndromex Ltd. | DIABETES TREATMENT REGIMENS USING α,α-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES |
US10512624B2 (en) | 2016-11-30 | 2019-12-24 | Syndromex Ltd. | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 |
US11407705B2 (en) | 2019-06-21 | 2022-08-09 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11613511B2 (en) | 2019-06-21 | 2023-03-28 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11760714B2 (en) | 2019-06-21 | 2023-09-19 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11926584B2 (en) | 2019-06-21 | 2024-03-12 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11987548B2 (en) | 2019-06-21 | 2024-05-21 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
Also Published As
Publication number | Publication date |
---|---|
EP0988274A4 (en) | 2000-10-18 |
JP5479857B2 (en) | 2014-04-23 |
EP0988274B1 (en) | 2009-05-20 |
EP2112134B1 (en) | 2013-10-30 |
CA2277075A1 (en) | 1998-07-16 |
KR20070026888A (en) | 2007-03-08 |
US6284903B1 (en) | 2001-09-04 |
EP2112134A1 (en) | 2009-10-28 |
AU7994798A (en) | 1998-08-03 |
KR20000069934A (en) | 2000-11-25 |
ATE431816T1 (en) | 2009-06-15 |
CA2277075C (en) | 2010-06-22 |
JP2001507713A (en) | 2001-06-12 |
EP0988274A1 (en) | 2000-03-29 |
US20020049345A1 (en) | 2002-04-25 |
IL119971A0 (en) | 1997-04-15 |
JP2010077141A (en) | 2010-04-08 |
KR100806927B1 (en) | 2008-02-22 |
IL119971A (en) | 2003-02-12 |
AU742945B2 (en) | 2002-01-17 |
DE69739415D1 (en) | 2009-07-02 |
US20040132818A1 (en) | 2004-07-08 |
KR100806928B1 (en) | 2008-02-22 |
US6800772B2 (en) | 2004-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6284903B1 (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
US4634795A (en) | Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
US4110351A (en) | Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts | |
US3784697A (en) | Pharmaceutical composition containing phenoxyalkane-carboxylic acids,salts and esters thereof | |
KR101708073B1 (en) | Loxoprofen derivative and pharmaceutical containing same | |
NO860661L (en) | ALFA, OMEGA-DICARBOXYLIC ACIDS, PROCEDURE FOR THE PREPARATION OF THESE AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS. | |
US20040213442A1 (en) | Novel fatty acids analogous | |
US3754021A (en) | 4-keto-4-(3-chloro-4'-cyclohexyl)phenylbutyric acid and related compounds | |
US4000164A (en) | Hypolipidemic agents | |
US5176933A (en) | Substituted succinate esters and low-calorie oils containing them | |
AU4085799A (en) | Novel diphenylethylene compounds | |
AU3436302A (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
NZ245201A (en) | An ethanolamine benzoate derivative and pharmaceutical compositions thereof | |
MXPA99006358A (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
HU185463B (en) | Process for producing cinnamoyl-cinnamic acid derivatives | |
US4305959A (en) | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | |
JPH03163042A (en) | Chalcone derivative | |
JPH072733B2 (en) | 5,6-Dihydro-4H-cyclopenta [b] thiophene-6-carboxylic acid, method for producing the same and pharmaceutical composition containing the same | |
SU1015622A1 (en) | 2-substituted 3-oxy-5-methyl-4-thiophenacetic acids possessing antiinflammatory and analgetic activity and method of producing same | |
JPS6054318B2 (en) | Method for producing aroyl-substituted phenyl acetic acid derivatives | |
JPH06316577A (en) | Ketorolac derivative markedly reduced in stimulas to stomach and intestines and formation of ulcer | |
JPH03291266A (en) | Pyrrole aldehyde derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1998 530697 Country of ref document: JP Kind code of ref document: A Ref document number: 2277075 Country of ref document: CA Kind code of ref document: A Ref document number: 2277075 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997006147 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/006358 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997949080 Country of ref document: EP Ref document number: 79947/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09331895 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997949080 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997006147 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 79947/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997006147 Country of ref document: KR |